List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 12.1. Antianginal medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
WHO Model List of Essential Medicines (2021) | 12.2. Antiarrhythmic medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
Guyana. Essential Medicines List. 2020-2021 | Restricted Medicines | No observations |
Suriname. NGK-C-011 | 12.1 Agents for Angina Pectoris | No observations |
Suriname. NGK-C-011 | 12.2 Antiarrhythmic drugs | No observations |
Suriname. NGK-C-011 | 12.3 Antihypertensives | No observations |
Suriname. NGK-C-011 | 12.4 Medicines for Heart Failure | No observations |
Haiti. National List of Essential Medicines | 12.01 Antianginals | No observations |
Barbados. Barbados National Drug Formulary (BNDF) | 24.24 Beta Adrenergic Blocking Agents | No observations |
List | Section | Observation |
---|---|---|
Haiti. National List of Essential Medicines | 12.03 Anti-hypertensives | No observations |
Haiti. National List of Essential Medicines | 12.04 Medicines for heart failure | No observations |
List | Section | Observation |
---|---|---|
Barbados. Barbados National Drug Formulary (BNDF) | 24.24 Beta Adrenergic Blocking Agents | No observations |
List | Section | Observation |
---|---|---|
Suriname. NGK-C-011 | 12.1 Agents for Angina Pectoris | No observations |
Suriname. NGK-C-011 | 12.2 Antiarrhythmic drugs | No observations |
Suriname. NGK-C-011 | 12.3 Antihypertensives | No observations |
Suriname. NGK-C-011 | 12.4 Medicines for Heart Failure | No observations |
Barbados. Barbados National Drug Formulary (BNDF) | 24.24 Beta Adrenergic Blocking Agents | No observations |
List | Section | Observation |
---|---|---|
Haiti. National List of Essential Medicines | 12.03 Anti-hypertensives | No observations |
Haiti. National List of Essential Medicines | 12.04 Medicines for heart failure | No observations |
List | Section | Observation |
---|---|---|
Peru | 12.4 Medications Used in Cardiac Insufficiency | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 12.1. Antianginal medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
WHO Model List of Essential Medicines (2021) | 12.2. Antiarrhythmic medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Includes metoprolol and carvedilol as alternatives. This medicine has the best evidence for effectiveness and safety. |
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
Suriname. NGK-C-011 | 12.1 Agents for Angina Pectoris | No observations |
Suriname. NGK-C-011 | 12.2 Antiarrhythmic drugs | No observations |
Suriname. NGK-C-011 | 12.3 Antihypertensives | No observations |
Suriname. NGK-C-011 | 12.4 Medicines for Heart Failure | No observations |
Haiti. National List of Essential Medicines | 12.01 Antianginals | No observations |